The HemOnc Pulse cover image

Part One: The Question of MRD in CLL Therapy

The HemOnc Pulse

CHAPTER

Exploring the Selection of BTKIs in Frontline Therapy

Exploring the considerations for selecting BTKIs in frontline therapy, focusing on toxicity profiles, patient comorbidities, and the tolerability of second-generation BTKIs like Daniel and Calibrietinib. Emphasizing patient-specific factors over efficacy differences, this chapter raises unanswered questions in the field.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner